FDA accepts review of Viatris and Mapi’s NDA filing for GA Depot
The US Food and Drug Administration (FDA) has accepted for review Viatris and Mapi Pharma’s new drug application (NDA) filed for GA Depot.
The US Food and Drug Administration (FDA) has accepted for review Viatris and Mapi Pharma’s new drug application (NDA) filed for GA Depot.
What's Your Reaction?
